A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors


This is a study to evaluate the safety and tolerability of the study drug HBM4003, and to determine the maximum tolerated dose and/or recommended Phase 2 study dose of HBM4003. Participants will receive 3 escalating doses of HBM4003, with the possibility of a fourth, higher dose level following review by a Safety Committee. The study will also look at the anti-tumor activity of HBM4003.

Full Title of Study: “A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2020


  • Drug: HBM4003
    • Intravenous (IV) administration on days 1, 8, 15 and 22 of a 28-day treatment cycle.

Arms, Groups and Cohorts

  • Experimental: HBM4003
    • Up to 4 (28 day) cycles of treatment with the potential for a higher dose to be administered in each of cycle 2 and cycle 4.

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of subjects with Dose-Limiting Toxicity (DLT)
    • Time Frame: From Day 1 until disease progression or Day 28
    • Number of subjects who experience DLT events during 28 days after first administration of HBM4003, divided by the number of DLT-evaluable subjects

Secondary Measures

  • Objective Response Rate
    • Time Frame: Up to 28 months
    • Proportion of subjects with best overall response of complete response (CR) or partial response (PR) per RECIST 1.1 and per Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST)
  • Duration of response
    • Time Frame: Up to 28 months
    • Time interval from first occurrence of a documented objective response to the time of disease progression, as determined by the Investigator using RECIST 1.1 or death from any cause, whichever comes first.
  • Disease control rate
    • Time Frame: Up to 28 months
    • Proportion of subjects with a best overall response of complete response (CR), partial response (PR) or stable disease (SD).
  • Duration of disease control
    • Time Frame: Up to 28 months
    • Time from data of start of treatment to the date of disease progression or death for subjects who had CR or PR or SD during treatment.
  • Tumor shrinkage (The percentage of patients with tumor shrinkage)
    • Time Frame: Up to 28 months
    • Greatest tumor shrinkage achieved at any follow-up assessment. Measured by radiological (computed tomography [CT]/Magnetic Resonance Imaging [MRI]) scanning until documented radiographic disease progression according to RECIST 1.1, or loss of clinical benefit after disease progression according to RECIST 1.1
  • Cmax (Maximum serum concentration)
    • Time Frame: Up to 28 months
  • Tmax (Time to reach maximum serum concentration)
    • Time Frame: Up to 28 months
    • Plasma
  • AUC0-tau (Area under the serum concentration versus time curve from time zero to the dosing interval tau
    • Time Frame: Up to 28 months
  • AUC0-inf (Area under the serum concentration versus time curve from time zero to infinity
    • Time Frame: Up to 28 months
  • t1/2 (Terminal half-life)
    • Time Frame: Up to 28 months
  • Clearance (CL)
    • Time Frame: Up to 28 months
  • Vss (Volume of distribution at steady state)
    • Time Frame: Up to 28 months

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent form and willingness to comply study requirements.
  • Confirmed advanced solid tumors that have progressed after treatment with standard therapies, or for which no effective standard therapy is available, or the subject refuses or has a contraindication to standard therapy.
  • Adequate organ and bone marrow function.
  • Females of childbearing potential may participate provided they agree to practice abstinence; and, if heterosexually active, agree to use at least 2 highly effective contraceptive methods throughout the study and for 3 months following the last dose of study drug; and have a negative serum pregnancy test.
  • Females of non-childbearing potential must be post-menopausal or have been surgically sterilized.
  • Male subjects with a female partner of childbearing potential must agree to practice abstinence or to use a physician-approved contraceptive method throughout the study and for 3 months following the last does of study drug.

Exclusion Criteria

  • Participation in another clinical study at the same time.
  • History of severe allergic diseases, history of severe drug allergy, or are known to be allergic to macromolecular protein preparations or any component of the study drug.
  • Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of the study drug:

1. CTLA-4 antibody within 6 weeks of study drug administration;

2. Any PD-1 or PD-L1 or Programmed cell death protein ligand 2 (PDL2)-directed antibody within 4 weeks of study drug administration;

3. Any other anticancer therapy within 2 weeks of the start of the study;

4. Anti-tumor vaccines within 3 months prior to study drug administration;

5. Live vaccine within 4 weeks prior to study drug administration or planned live vaccine during study period;

6. Corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 2 weeks of study drug administration; Nasal spray, inhalation, topical corticosteroids or physiological doses of systemic corticosteroids are not included.

  • Major surgical procedure(s) within 28 days prior to first dose of study drug.
  • Failure to recover from any immune-related toxicity from prior cancer therapy, or any other toxicity related to previous anticancer treatment, with the exception of alopecia.
  • Combination medication or treatments to be excluded:

1. Any concurrent chemotherapy, radiotherapy, immunotherapy, or biological therapy for cancer treatment. Concurrent use of hormones on a stable dose for non-cancer related conditions is acceptable. Androgen deprivation therapy (ADT) for advanced prostate cancers is acceptable. Local treatment of isolated non-target lesions for palliative intent is acceptable;

2. Any traditional anti-tumor herbal medications;

3. Receipt of red blood cells or platelets infusion, granulocyte colony stimulating factor (G-CSF) or granulocyte monocyte colony stimulating factor (GM-CSF) within 1 week of the first dose of study drug.

  • Have other diseases that may affect the effectiveness and safety of the study drug, such as:

1. Known brain metastases or other central nervous system metastases that is either symptomatic or untreated, that requires concurrent treatment;

2. Active infection requiring treatment of antibiotics within 14 days prior to first dose of study drug;

3. Known history of infection of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS), human T lymphotropic virus 1, hepatitis B virus, or active hepatitis C virus;

4. Active known or suspected autoimmune disease or a history of autoimmune disease, including but not limited to inflammatory bowel disease, autoimmune hepatitis, Guillain-Barre syndrome.

5. Known primary immunodeficiency;

6. Sever diarrhea, active gastrointestinal bleeding, or a history of Gastrointestinal perforation, acute diverticulitis, intra-abdominal abscess or gastrointestinal obstruction;

(b) Have received allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, or have received autologous hematopoietic stem cell transplantation within 3 months prior to the first dose of study drug.

  • Subjects with major cardiovascular disease.
  • History of other uncured malignant diseases, except for non-melanoma skin cancer in situ, superficial bladder cancer, cervical cancer in situ that has been curatively resected, and localized prostate cancer managed by active surveillance.
  • Pregnant or breastfeeding women.

Other protocol-defined inclusion/exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Harbour BioMed US Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Maria, +86 021-5339-9017, maria.deassis@harbourbiomed.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.